Autonomix Medical Showcases Long-Term Pancreatic Cancer Pain Study at 2026 ASCO Symposium
Reuters
Yesterday
Autonomix Medical Showcases Long-Term Pancreatic Cancer Pain Study at 2026 ASCO Symposium
Autonomix Medical Inc. has announced that its abstract titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation" has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The presentation, to be delivered by Chief Medical Officer Robert S. Schwartz, MD, will take place on January 9, 2026, in San Francisco, California. The results of the study will be presented at the symposium and have not yet been disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604400-en) on December 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.